STM-416p injection during prostate removal surgery
Part of Cancer, Kidney & urinary clinical trials.
This trial tests an injection called STM-416p given during prostate removal surgery to see if it can help prevent prostate cancer from coming back. It may be an option for men with intermediate to high-risk prostate cancer who are already planning to have their prostate removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man aged 18 or older.
- You have been diagnosed with prostate cancer and are scheduled for prostate removal surgery within 28 days.
- Your cancer is Grade Group 2–5 (higher than the lowest risk group).
- You are generally well enough to perform daily activities (ECOG score 0–2).
- You have adequate organ and bone marrow function (checked by blood tests).
- You do not have other active cancers, allergies to the study drug, or a history of organ transplant or immune deficiency.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two radioactive drugs (177Lu-PSMA-617 and 225Ac-PSMA-617) given before prostate removal surgery in men with high-risk prostate cancer that has not spread far. The goal is to see which drug is better at shrinking the tumor and reducing the chance of cancer coming back.
This trial tests an experimental vaccine (2141-V11) combined with standard hormone therapy and an anti-androgen drug before prostate removal surgery. It aims to see if the combination can help the immune system fight the cancer more effectively.
This trial tests a precise type of radiation (called SBRT) to the prostate bed for men whose PSA starts rising after prostate removal surgery. It aims to see if this targeted approach can effectively treat the recurrence without needing long-term hormone therapy.
This trial tests a new way to find microscopic cancer cells (minimal residual disease) in the blood after prostate surgery. If successful, it could help doctors decide if additional treatment is needed.
This trial tests a new immunotherapy drug (REGN5678) given before surgery to men with high-risk prostate cancer that hasn't spread. The goal is to see if the drug can shrink or control the cancer before the prostate is removed.
This trial tests whether using a PSMA-PET scan before prostatectomy can guide surgery in a way that helps preserve sexual function. It may be most helpful if you have certain kinds of prostate cancer and want to keep erections after surgery.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.